cellebrite di ltd - CLBT

CLBT

Close Chg Chg %
19.46 -0.03 -0.15%

Closed Market

19.43

-0.03 (0.15%)

Volume: 1.25M

Last Updated:

Mar 31, 2025, 4:00 PM EDT

Company Overview: cellebrite di ltd - CLBT

CLBT Key Data

Open

$19.02

Day Range

18.75 - 19.46

52 Week Range

10.25 - 26.30

Market Cap

$4.66B

Shares Outstanding

239.47M

Public Float

107.51M

Beta

1.52

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.39

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.34M

 

CLBT Performance

1 Week
 
0.00%
 
1 Month
 
4.85%
 
3 Months
 
-11.67%
 
1 Year
 
75.63%
 
5 Years
 
N/A
 

CLBT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About cellebrite di ltd - CLBT

Cellebrite DI Ltd. engages in the provision of digital investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Its services include training and advisory, value realization, advanced services, and technical customer support. The firm also offers software solutions and analytic tools designed to accelerate digital investigations and address the growing complexity of handling crime and security challenges in the digital era. The company was founded on April 13, 1999 and is headquartered in Petach Tikva, Israel.

CLBT At a Glance

Cellebrite DI Ltd.
94 Shlomo Shmelzer Road
Petach Tikva, HaMerkaz 4970602
Phone 972-73-394-8000 Revenue 401.20M
Industry Packaged Software Net Income -283,007,000.00
Sector Technology Services 2024 Sales Growth 23.405%
Fiscal Year-end 12 / 2025 Employees 1,167
View SEC Filings

CLBT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 11.502
Price to Book Ratio 15.376
Price to Cash Flow Ratio 34.914
Enterprise Value to EBITDA 61.689
Enterprise Value to Sales 10.415
Total Debt to Enterprise Value 0.003

CLBT Efficiency

Revenue/Employee 343,790.06
Income Per Employee -242,508.141
Receivables Turnover 4.871
Total Asset Turnover 0.649

CLBT Liquidity

Current Ratio 1.901
Quick Ratio 1.866
Cash Ratio 1.513

CLBT Profitability

Gross Margin 84.399
Operating Margin 14.239
Pretax Margin -68.789
Net Margin -70.54
Return on Assets -45.758
Return on Equity -152.881
Return on Total Capital -81.561
Return on Invested Capital -146.547

CLBT Capital Structure

Total Debt to Total Equity 3.264
Total Debt to Total Capital 3.161
Total Debt to Total Assets 1.575
Long-Term Debt to Equity 2.037
Long-Term Debt to Total Capital 1.972
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cellebrite Di Ltd - CLBT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
246.25M 270.65M 325.11M 401.20M
Sales Growth
- +9.91% +20.12% +23.41%
Cost of Goods Sold (COGS) incl D&A
42.56M 50.75M 53.23M 62.59M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
7.01M 9.19M 10.01M 10.61M
Depreciation
5.04M 6.37M 6.66M 7.26M
Amortization of Intangibles
1.97M 2.83M 3.35M 3.35M
COGS Growth
- +19.24% +4.90% +17.59%
Gross Income
203.69M 219.91M 271.88M 338.61M
Gross Income Growth
- +7.96% +23.63% +24.54%
Gross Profit Margin
+82.72% +81.25% +83.63% +84.40%
2021 2022 2023 2024 5-year trend
SG&A Expense
189.87M 216.90M 238.60M 281.48M
Research & Development
65.54M 80.62M 84.39M 98.42M
Other SG&A
124.33M 136.28M 154.21M 183.07M
SGA Growth
+130,066.25% +14.24% +10.00% +17.97%
Other Operating Expense
- - - -
-
Unusual Expense
(67.87M) (114.90M) 119.39M 349.82M
EBIT after Unusual Expense
81.69M 117.91M (86.11M) (292.70M)
Non Operating Income/Expense
1.17M 4.08M 11.30M 18.32M
Non-Operating Interest Income
1.12M 2.34M 10.72M 18.22M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
564.00K 1.23M 753.00K 1.60M
Interest Expense Growth
- +117.55% -38.63% +112.62%
Gross Interest Expense
564.00K 1.23M 753.00K 1.60M
Interest Capitalized
- - - -
-
Pretax Income
82.31M 120.76M (75.56M) (275.98M)
Pretax Income Growth
+642.34% +46.72% -162.57% -265.24%
Pretax Margin
+33.42% +44.62% -23.24% -68.79%
Income Tax
10.91M (45.00K) 5.54M 7.02M
Income Tax - Current - Domestic
9.66M (2.57M) 3.01M 10.01M
Income Tax - Current - Foreign
2.88M 4.92M (2.88M) 588.00K
Income Tax - Deferred - Domestic
(10.00K) (85.00K) 1.60M (3.16M)
Income Tax - Deferred - Foreign
(1.63M) (2.31M) 3.81M (417.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - (4.69M)
-
Consolidated Net Income
71.40M 116.11M (81.10M) (283.01M)
Minority Interest Expense
- - - -
-
Net Income
71.40M 116.11M (81.10M) (283.01M)
Net Income Growth
+570.46% +62.63% -169.85% -248.96%
Net Margin Growth
+28.99% +42.90% -24.95% -70.54%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
71.40M 116.11M (81.10M) (283.01M)
Preferred Dividends
- - - -
-
Net Income Available to Common
71.40M 116.11M (81.10M) (283.01M)
EPS (Basic)
0.4958 0.6355 -0.4265 -1.351
EPS (Basic) Growth
+345.08% +28.18% -167.11% -216.76%
Basic Shares Outstanding
144.00M 182.69M 190.15M 209.47M
EPS (Diluted)
0.442 0.5942 -0.4265 -1.351
EPS (Diluted) Growth
+318.49% +34.43% -171.78% -216.76%
Diluted Shares Outstanding
161.54M 195.39M 190.15M 209.47M
EBITDA
20.83M 12.20M 43.29M 67.73M
EBITDA Growth
+8,915.39% -41.44% +254.92% +56.45%
EBITDA Margin
+8.46% +4.51% +13.32% +16.88%

Snapshot

Average Recommendation BUY Average Target Price 24.857
Number of Ratings 8 Current Quarters Estimate 0.065
FY Report Date 06 / 2025 Current Year's Estimate 0.30
Last Quarter’s Earnings 0.05 Median PE on CY Estimate N/A
Year Ago Earnings -1.35 Next Fiscal Year Estimate 0.357
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 8 7
Mean Estimate 0.06 0.09 0.30 0.36
High Estimates 0.12 0.14 0.51 0.51
Low Estimate 0.05 0.07 0.25 0.28
Coefficient of Variance 35.25 24.18 28.84 21.50

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 8
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Cellebrite Di Ltd in the News